SEC Form 10-K filed by Akebia Therapeutics Inc.
$AKBA
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/4/2025 | $8.00 | Buy | H.C. Wainwright |
| 4/28/2025 | $7.00 | Outperform | Leerink Partners |
| 4/1/2025 | $6.00 | Buy | Jefferies |
| 11/29/2023 | $4.00 | Buy | BTIG Research |
| 8/28/2023 | $3.75 | Neutral → Buy | H.C. Wainwright |
| 5/31/2023 | $2.00 → $4.00 | Neutral → Overweight | Piper Sandler |
| 3/31/2022 | $10.00 → $2.00 | Buy → Neutral | H.C. Wainwright |
| 3/31/2022 | Buy → Hold | Needham |